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Hepatorenal Syndrome in the Emergency Department: 
A Case Report
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Abstract
Background: Hepatorenal syndrome is a condition where there is functional renal failure in a background of liver disease. It is relatively 
common in patients with liver cirrhosis and is associated with a high mortality rate if untreated. Case: This is a case report of an 88-year-old 
Chinese man presenting from a community hospital with a new onset of abdominal distension on a background of cryptogenic liver cirrhosis 
diagnosed on computed tomography  scan. Clinical history and physical findings were consistent with that of fluid overload. Investigations 
performed indicated acute kidney injury together with liver failure secondary to liver cirrhosis. The patient was diagnosed with hepatorenal 
syndrome in accordance with the criteria established by the International Ascites Club and managed with an infusion of vasopressin and 
albumin in the emergency department. He was subsequently admitted to the general ward (gastrology), where he was managed for hepato-
renal syndrome, improved clinically and was discharged to the nursing home. Conclusion: Hepatorenal syndrome can be managed effectively 
with albumin and vasopressin, and such treatment can be started as early as in the emergency department. Acute care physicians should 
not be hesitant in diagnosing and treating hepatorenal syndrome as early as in the emergency department for appropriate patients.
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Introduction
Hepatorenal syndrome (HRS) is a potentially reversible condi-
tion where there is functional renal failure in a background of 
liver disease. It is relatively common, with an incidence of 1 in 
10 hospitalized patients with liver cirrhosis in the United States 
of America.1 This is of great concern given the high mortality 
rate associated with HRS if left untreated. Type 1 HRS is asso-
ciated with rapid progression to renal failure over as short a 
period as two weeks, compared to Type 2 HRS which is associa-
ted with a slow but steady progressive course with refractory 
ascites. Median survival time in patients with untreated type 
1 HRS is two to four weeks, with 95% of such patients dying 
within the first 30 days of onset. Those with type 2 HRS have 
a median survival time of 6 months.2 The International Ascites 
Club (IAC) has provided a set of criteria revised in 2005 to aid 
in the diagnosis of HRS (Table 1).
Given the high mortality rate associated with untreated HRS 
and the potential to reverse this syndrome, it is of utmost im-
portance for clinicians to identify patients with HRS as per the 
IAC criteria and initiate appropriate treatment as soon as pos-
sible.2 This report concerns a patient presenting to the emer-
gency department of a tertiary hospital with HRS. This report 
serves to highlight the role acute care practitioners can play in 
diagnosing HRS and starting treatment early. The case reports 
statement (CARE) framework was followed in the drafting of 
this case report.
The Case
An 88-year-old Chinese man was referred from a communi-
ty hospital when the caregiver noted abdominal distension 
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          Key Points:
• Hepatorenal syndrome is a common complication of liver cirrhosis.
• If left untreated, hepatorenal syndrome, particularly type 1 with spon-
taneous bacterial peritonitis, is associated with a high mortality rate.
• Albumin and vasopressors have been proven to be a good treatment 
option for hepatorenal syndrome.
• Early institution of treatment is important in managing hepatorenal syn-
drome, and treatment may be instituted as early as in the emergency de-
partment.
(Available from: http://www.icascites.org/about/guidelines/, updated 2005 Nov; cited 2014 Nov 16).
while aiding the patient in rehabilitation. The patient had a 
past medical history of type 2 diabetes mellitus, hypertension, 
paroxysmal atrial fibrillation (PAF) and sick sinus syndrome 
for which he had a VVI pacemaker inserted, right hemispheric 
syndrome secondary to right middle cerebral artery infarction 
complicated by hemorrhagic conversion, and a background of 
1. Presence of cirrhosis and ascites
2. Serum creatinine >1.5 mg/dL (or 133 µmol/L)
3. No improvement of serum creatinine (decrease equal to or less than 
1.5 mg/dL) after at least 48 hours of diuretic withdrawal and volume 
expansion with albumin (recommended dose: 1 g/kg b.w. per day up to a 
maximum of 100 g of albumin/day)
4. Absence of shock
5. No current or recent treatment with nephrotoxic drugs
6. Absence of parenchymal kidney disease as indicated by proteinuria 
>500 mg/day, microhematuria (>50 red blood cells/high power field, and/
or abnormal renal ultrasound scanning
Table 1. The International Club of Ascites Criteria for the Diagnosis 
of Hepatorenal Syndrome.
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cryptogenic liver cirrhosis corroborated with computed tomo-
graphy (CT) findings which showed established liver cirrhosis 
and no evidence of obstructive nephropathy or parenchymal 
disease. He was on gliclazide and metformin for diabetes con-
trol, atorvastatin for dyslipidemia, amlodipine, enalapril and 
bisoprolol for hypertension, and aspirin for PAF. There was no 
recent change in medications.
On physical examination, the patient had anasarca, with a 
body temperature of 37.2 °C, pulse rate of 60 beats per minute, 
respiratory rate of 16 breaths per minute, blood pressure of 
132/72 mmHg, and oxygen saturation of 100% on room air. The 
patient was drowsy, groaned and localized pain. His abdomen 
was soft and distended, with a positive fluid thrill and shifting 
dullness. Pitting edema was noted in bilateral lower limbs. Car-
diovascular and respiratory examination yielded no significant 
findings, and the lungs were clear on auscultation. The patient 
was managed in the resuscitation area.
Hematological investigations were performed. Liver panel 
showed transaminitis with elevated alanine transaminase (ALT) 
at 78 U/L and aspartate transaminase (AST) at 77 U/L (Table 2). 
Renal panel showed markedly elevated urea at 37.8 mmol/L 
and mildly elevated creatinine at 133.0 µmol/L at presentation, 
rising from a baseline of 12.9 mmol/L for urea and 83.0 µmol/L 
for creatinine at one month prior to presentation. Mild hyper-
kalemia was also noted with a serum potassium level of 5.9 
mmol/L. Other hematological investigations had values within 
normal ranges. Initial urinalysis showed no evidence suggesti-
ve of a parenchymal kidney disease, with the absence of pro-
teinuria and microscopic hematuria. Analysis of the ascitic fluid 
ruled out occult sources of infection in this patient. 
Differential diagnoses considered included fluid overload se-
condary to acute renal failure and deterioration of clinical con-
dition secondary to underlying liver cirrhosis. The diagnosis 
of HRS could not be excluded based on the patient’s clinical 
presentation. The patient had a background of cirrhosis and 
ascites and was not on any nephrotoxic drugs. He was not 
clinically in shock and was hemodynamically stable. Serum 
creatinine was elevated at 133.0 µmol/L with no evidence of 
parenchymal kidney disease. Considering the above clinical 
and laboratory findings together with the presentation of re-
nal failure in a background of liver cirrhosis, the patient was 
provisionally diagnosed with HRS as per the IAC criteria (Table 1). 
With the prompt diagnosis, he was started on intravenous (IV) 
infusion of vasopressin at a rate of 0.01 U/min and albumin 
5% in 500 ml over two hours. IV insulin at 5 U/h and IV dex-
trose 5% in 500 ml over eight hours were also started for the 
management of hyperglycemia. A nasogastric tube was also 
inserted for enteral nutrition given a previous history of dys-
phagia secondary to right middle cerebral artery infarction with 
hemorrhagic conversion.
In view of the diagnosis, the patient was admitted to the gene-
ral medicine ward (gastrology). The patient’s diagnosis of HRS 
was confirmed in the ward setting, and he was managed accor-
dingly. He subsequently improved clinically and was discharged 
to a nursing home.
Discussion
This case report demonstrated that HRS can be diagnosed 
early and managed accordingly even in the acute care setting.3 
Diagnosis of HRS can be achieved with the aid of the criteria 
developed by IAC, and appropriate treatment can be started 
even before the patient is admitted to the ward. 
The pathogenesis of HRS is currently still being explored. Arte-
rial vasodilatation of the splanchnic circulation associated with 
the local release of vasodilatory substances is considered as a 
possible explanation. Renal vasoconstriction in the absence of 
reduced cardiac output and blood volume may also contribute 
to the development of HRS.4 A high index of suspicion for HRS 
should be present in all cases with liver cirrhosis presenting 
with non-specific symptoms such as malaise and an acute 
decline in renal function.2 It must also be noted that patients 
with type 1 HRS associated with spontaneous bacterial 
peritonitis have almost 100% hospital mortality rate if appropriate 
treatment is not provided.5 
Given the wide variety of causes which may be associated with 
renal failure in patients with underlying cirrhosis, the IAC deve-
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Test Reference Range Feb 2014 Mar 2014
Urea, serum (mmol/L) 2.8 – 7.7 12.9 37.8
Sodium, serum (mmol/L) 135.0 – 145.0 135.0 146.0
Potassium, serum (mmol/L) 3.5 – 5.3 4.5 5.9
Chloride, serum (mmol/L) 96.0 – 108.0 109.0 119.0
Bicarbonate, serum (mmol/L) 19.0 – 31.0 17.0 15.0
Glucose, serum (mmol/L) 3.1 – 7.8 7.2 16.5
Creatinine, serum (µmol/L) 50 – 90 83 133
Albumin, serum (g/L) 37 – 51 N/A 24
Alanine transaminase, serum (U/L) 10 – 55 N/A 78
Aspartate transaminase, serum (U/L) 10 – 45 N/A 77
Red blood cells, urine (cells/high power field) 0 – 3 N/A 0
White blood cells, urine (cells/high power field) 0 – 6 N/A 13
Epithelial cells, urine (cells/high power field) 0 – 4 N/A 0
Protein, urine Negative N/A Negative
Table 2. Relevant Findings of Renal and Liver Function Tests and Urinalysis at Presentation and One Month Prior to Presentation.
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loped a revised set of criteria in 2005 to aid in the diagnosis of 
HRS.3 The utility of such criteria cannot be understated. With a 
10% incidence rate among hospitalized patients and with the 
high morbidity and mortality associated with untreated HRS, 
early diagnosis and institution of appropriate treatment is of 
definite importance in these patients.1,2,6 
The mainstay of therapy for patients with HRS remains liver 
transplantation. Published literature has shown the effective-
ness of transplantation in ensuring survival and good renal 
function in patients with HRS.7 It must however be noted that 
liver transplantation may not be suitable for all HRS patients. 
The unsuitability for liver transplantation, coupled with the 
long waiting times at most transplant centers, demands the 
search for alternative therapies for HRS.
Several pharmacological options are available in the manage-
ment of HRS. While vasodilators such as dopamine were initia-
lly thought to be effective, the current practice has shifted to 
the use of vasoconstrictors. Several studies have shown that 
vasoconstrictors acting on the splanchnic circulation, including 
vasopressin and its analogues terlipressin and ornipressin, are 
able to improve patient outcome. It is postulated that these 
vasoconstrictors have an effect on the splanchnic circulation, 
reversing the vasodilatory effect usually found in HRS.8 Despite 
a trial showing that terlipressin is more effective than nore-
pinephrine in treating HRS, the utility of norepinephrine and 
other similar drugs as an alternative must not be discounted.9
The use of albumin together with vasopressors has also been 
shown to provide a good outcome, particularly in patients diag-
nosed with type 1 HRS associated with spontaneous bacterial 
peritonitis.5 The IAC has recommended the use of albumin as 
the preferred volume expander in patients with HRS.3 For this 
reason, a combination therapy involving both albumin and a 
suitable vasopressor such as terlipressin should be considered 
when initiating pharmacological management of HRS.
The strengths of this case report include the fact that there is 
little literature regarding prompt diagnosis and treatment of 
HRS, particularly in the acute care setting. We demonstrated 
that HRS can be diagnosed promptly using the criteria deve-
loped by IAC and managed accordingly even in the acute care 
setting. As the corroborative literature mentioned in the dis-
cussion has shown, early measures to tackle HRS are important 
in providing a better outcome for these patients. 
We acknowledge the limitations of our case report. Given that 
this patient was managed in the acute care setting, the luxury 
of time was not afforded to us in our management of the case. 
Hence, the primary priority in this case was to provide acute 
care for the patient and to stabilize him for further treatment 
by the gastrologist in the ward setting. In this instance, other 
investigations such as ascitic fluid analysis to rule out sponta-
neous bacterial peritonitis could only be performed after the 
patient was transferred to the ward. 
Conclusion
Several learning points can be obtained from this case re-
port. From the above discussion regarding medical literature 
concerning HRS, early diagnosis and initiation of appropriate 
treatment is definitely important in managing HRS. Acute care 
clinicians should consider HRS as a possible diagnosis in pa-
tients presenting with a new onset of renal failure and with a 
background of liver cirrhosis. Albumin and vasopressors can 
and should be started as early as in the emergency depart-
ment in patients who are suspected of having HRS. Acute care 
physicians should not be hesitant in diagnosing and starting 
the treatment of HRS in the appropriate patients particularly in 
the emergency department. Further studies to be considered 
include investigating the benefit of starting HRS treatment in 
the emergency department as compared to the ward setting.
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